Literature DB >> 2714347

A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives.

E E Voest1, J C van Houwelingen, J P Neijt.   

Abstract

We performed a meta-analysis of 38 articles containing 66 treatment groups and 3443 patients in order to evaluate prognostic factors in advanced epithelial ovarian cancer. To evaluate overall survival we designed a method to summarize the overall survival curve into one single figure: the log (relative risk) (LRR). This is the first meta-analysis using overall survival (measured with the LRR) as an objective. We found that the main prognostic factors predicting an improved survival (measured with the LRR) are: chemotherapy including cisplatin as initial treatment, a residual tumour mass of less than 2 cm prior to therapy, FIGO stage II/III and a good performance status. In a multivariate model, the use of cisplatin and the residual tumour were found to be the only factors of prognostic relevance. No relation between median survival and the overall clinical response rate of all patients entered in the denominator, could be demonstrated. Undifferentiated tumours and patients treated with cisplatin regimens had higher response rates to treatment but younger patients and those with endometrioid histology were less likely to respond. A surgical complete remission was encountered more frequently among studies that included a high number of patients with small tumour masses prior to treatment. Trials using cisplatin included more patients with small tumour nodules in their patient material compared to studies not using this drug. The data illustrate the danger of comparing studies with each other. In the trials with a high percentage of patients with small tumour residuals in the study population more toxic deaths were seen. This probably reflects the fact that they had received more intensive treatment. The LRR correlated strongly with the median survival, response and the percentage of surgical complete remissions. We concluded that the introduction of the LRR can be a meaningful addition to the evaluation of the influence of prognostic factors on overall survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714347     DOI: 10.1016/0277-5379(89)90208-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  12 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  The function of COX-2 in human ovarian carcinoma.

Authors:  Roshan Agarwal
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.

Authors:  M Brinkhuis; J P Baak; G A Meijer; P J van Diest; O Mogensen; P Bichel; J P Neijt
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

4.  Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Authors:  Michelle L Harrison; Martin E Gore; David Spriggs; Stan Kaye; Alexia Iasonos; Martee Hensley; Carol Aghajanian; Ennapadam Venkatraman; Paul Sabbatini
Journal:  Gynecol Oncol       Date:  2007-07-05       Impact factor: 5.482

Review 5.  Survivorship as an element of clinical trials in ovarian cancer.

Authors:  Jessica N McAlpine; Lari B Wenzel
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

6.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

7.  The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.

Authors:  K Karrer; H Salzer; P Sevelda; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

9.  An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer.

Authors:  D J Cruickshank; J Paul; C R Lewis; E J McAllister; S B Kaye
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

10.  Management of ovarian cancer: referral to a multidisciplinary team matters.

Authors:  E J Junor; D J Hole; C R Gillis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.